文 献1）Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 2011; 6(7): 1242-6. 2）Minegishi Y, Kuribayashi H, Kitamura K, Mizutani H, Kosaihira S, Okano T, et al. The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J Thorac Oncol 2011; 6(4): 801-7. 3）Yoshida T, Yoh K, Goto K, Niho S, Umemura S, Ohmatsu H, et al. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease. Anticancer Res 2013; 33(3): 1175-9. 4）Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, et al. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res 2020; 6(2): 00184-2019. 5）日本呼吸器学会腫瘍学術部会・びまん性肺疾患学術部会. 間質性肺炎合併肺癌に関するステートメント. 南江堂、2017. 6）Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phaseⅡstudy of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011; 29(16): 2215-22. 7）Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al. Italian, multicenter, phaseⅢ, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol 2017; 35(12): 1281-7. 8）Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, et al. Randomized phaseⅡ-Ⅲstudy of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol 2015; 26(5): 908-14. 9）Han JY, Kim HY, Lim KY, Hwangbo B, Lee JS. A phaseⅡstudy of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer 2016; 96: 108-12.10）Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22): 2071-82. 11）Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A, et al. Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis. Clin Lung Cancer 2018; 19(1): e5-e9. 12）Ikeda S, Ogura T, Kato T, Kenmotsu H, Iwasawa T, Misumi T, et al. Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phaseⅡstudy of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Ther Adv Med Oncol 2020; 12: 1758835920923431.8
元のページ ../index.html#22